Creating a vaccine to protect against all COVID-19 variants
Development of a Pan-COVID-19 Vaccine Candidate
This study is working on a new COVID-19 vaccine that hopes to protect against different strains of the virus, including new ones, using a special technology that has been successful before, and it's designed to help your body build a strong defense against future infections.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | RNA Therapeutics INC. NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10819607 on NIH RePORTER |
What this research studies
This research focuses on developing a pan-COVID-19 vaccine that aims to provide broad protection against various strains of the virus, including emerging variants. The approach utilizes mRNA technology, which has shown promise in previous vaccine developments. The vaccine candidate expresses a conserved protein from the virus, which has demonstrated strong immune responses in animal studies. By targeting a more stable part of the virus, the goal is to enhance immunity and reduce the risk of future outbreaks.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of COVID-19 infection, including those with underlying health conditions or those in high-exposure environments.
Not a fit: Patients who are already fully vaccinated with existing COVID-19 vaccines may not receive additional benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective vaccine that protects against multiple COVID-19 variants, potentially reducing hospitalizations and deaths.
How similar studies have performed: Other research has shown success with mRNA vaccine technology, particularly in the rapid development of COVID-19 vaccines, indicating a promising avenue for this novel approach.
Where this research is happening
Newark, UNITED STATES
- RNA Therapeutics INC. — Newark, United States (Active)
Researchers
- Principal investigator: Hu, Haitao — RNA Therapeutics INC.
- Study coordinator: Hu, Haitao
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.